{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:28Z","timestamp":1792783528015,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"University of Otago","id":[{"id":"https:\/\/ror.org\/01jmxt844","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01712-3","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:45:45Z","timestamp":1790858745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Brand Switching: A Regulatory Perspective"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-6543","authenticated-orcid":false,"given":"Ping Siu","family":"Kee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-5191","authenticated-orcid":false,"given":"Paul K. L.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-248X","authenticated-orcid":false,"given":"Michael","family":"Tatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6574-1246","authenticated-orcid":false,"given":"Rhiannon","family":"Braund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6445-8526","authenticated-orcid":false,"given":"Martin A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7779-5206","authenticated-orcid":false,"given":"Simran D. S.","family":"Maggo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"9","key":"1712_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA. 2020;323(9):844\u201353. https:\/\/doi.org\/10.1001\/jama.2020.1166.","journal-title":"JAMA"},{"issue":"2","key":"1712_CR2","doi-asserted-by":"publisher","first-page":"e0171284","DOI":"10.1371\/journal.pone.0171284","volume":"12","author":"M Ewen","year":"2017","unstructured":"Ewen M, Zweekhorst M, Regeer B, Laing R. Baseline assessment of WHO\u2019s target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS ONE. 2017;12(2):e0171284. https:\/\/doi.org\/10.1371\/journal.pone.0171284.","journal-title":"PLoS ONE"},{"key":"1712_CR3","unstructured":"U.S Food and Drug Administration. First generic drug approvals [Internet]. 2025 [accessed 2026 Feb 8]. https:\/\/www.fda.gov\/drugs\/drug-and-biologic-approval-and-ind-activity-reports\/first-generic-drug-approvals."},{"issue":"3","key":"1712_CR4","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1097\/mjt.0000000000000282","volume":"24","author":"RJ Straka","year":"2017","unstructured":"Straka RJ, Keohane DJ, Liu LZ. Potential clinical and economic impact of switching branded medications to generics. Am J Ther. 2017;24(3):e278\u201389. https:\/\/doi.org\/10.1097\/mjt.0000000000000282.","journal-title":"Am J Ther"},{"issue":"4","key":"1712_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/ehjcvp\/pvy035","volume":"5","author":"VL Serebruany","year":"2019","unstructured":"Serebruany VL, Hall TS, Atar D, Agewall S, Hyun Kim M, Geudelin B, et al. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):210\u20135. https:\/\/doi.org\/10.1093\/ehjcvp\/pvy035.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"1","key":"1712_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12325-021-01969-3","volume":"39","author":"L Wang","year":"2022","unstructured":"Wang L, Chen YJ, Grabner M, Nepal B, Bodhani A, Espaillat R, et al. Comparative effectiveness of persistent use of a name-brand levothyroxine (Synthroid(R)) vs. persistent use of generic levothyroxine on TSH goal achievement: a retrospective study among patients with hypothyroidism in a managed care setting. Adv Ther. 2022;39(1):779\u201395. https:\/\/doi.org\/10.1007\/s12325-021-01969-3.","journal-title":"Adv Ther"},{"issue":"1","key":"1712_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40258-014-0147-0","volume":"13","author":"H Gothe","year":"2015","unstructured":"Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, et al. The impact of generic substitution on health and economic outcomes: a systematic review. Appl Health Econ Health Policy. 2015;13(1):21\u201333. https:\/\/doi.org\/10.1007\/s40258-014-0147-0.","journal-title":"Appl Health Econ Health Policy"},{"issue":"10","key":"1712_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.003891","volume":"10","author":"J Leclerc","year":"2017","unstructured":"Leclerc J, Blais C, Rochette L, Hamel D, Gu\u00e9nette L, Poirier P. Impact of the commercialization of three generic angiotensin II receptor blockers on adverse events in Quebec, Canada. Circ Cardiovasc Qual Outcomes. 2017;10(10):e003891. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.003891.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"1712_CR9","doi-asserted-by":"publisher","first-page":"e2017645","DOI":"10.1001\/jamanetworkopen.2020.17645","volume":"3","author":"JP Brito","year":"2020","unstructured":"Brito JP, Ross JS, Sangaralingham L, Dutcher SK, Graham DJ, Wang Z, et al. Comparative effectiveness of generic vs brand-name levothyroxine in achieving normal thyrotropin levels. JAMA Netw Open. 2020;3(9):e2017645. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.17645.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1712_CR10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/cts.13590","volume":"16","author":"CC Chan","year":"2023","unstructured":"Chan CC, Tung YC, Lee KT, Chan YH, Chu PH. Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention in patients with acute myocardial infarction: a nationwide cohort study. Clin Transl Sci. 2023;16(9):1594\u2013605. https:\/\/doi.org\/10.1111\/cts.13590.","journal-title":"Clin Transl Sci"},{"issue":"Pt A","key":"1712_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yebeh.2015.08.014","volume":"52","author":"JJ Gagne","year":"2015","unstructured":"Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52(Pt A):14\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2015.08.014.","journal-title":"Epilepsy Behav"},{"key":"1712_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2147\/NDT.S98597","volume":"12","author":"N Kasemsap","year":"2016","unstructured":"Kasemsap N, Onsanit S, Chiewthanakul P, Kongbunkiat K, Tanking C, Vorasoot N, et al. Efficacy and motor complications of original and generic levodopa in Parkinson\u2019s disease treatment. Neuropsychiatr Dis Treat. 2016;12:1185\u20139. https:\/\/doi.org\/10.2147\/NDT.S98597.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"1712_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.hemonc.2020.06.002","volume":"14","author":"DP Lad","year":"2021","unstructured":"Lad DP, Malhotra P, Patil AN, Nampoothiri RV, Kasudhan KS, Khadwal A, et al. Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma. Hematol Oncol Stem Cell Ther. 2021;14(2):114\u20138. https:\/\/doi.org\/10.1016\/j.hemonc.2020.06.002.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"1712_CR14","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1377\/hlthaff.2010.0843","volume":"29","author":"DA Chokshi","year":"2010","unstructured":"Chokshi DA, Avorn J, Kesselheim AS. Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood). 2010;29(10):1842\u20138. https:\/\/doi.org\/10.1377\/hlthaff.2010.0843.","journal-title":"Health Aff (Millwood)."},{"issue":"10","key":"1712_CR15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.295.10.1172","volume":"295","author":"PC Gotzsche","year":"2006","unstructured":"Gotzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA. 2006;295(10):1172\u20134. https:\/\/doi.org\/10.1001\/jama.295.10.1172.","journal-title":"JAMA"},{"issue":"8","key":"1712_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.mayocp.2016.04.032","volume":"91","author":"ME Flacco","year":"2016","unstructured":"Flacco ME, Manzoli L, Boccia S, Puggina A, Rosso A, Marzuillo C, et al. Registered randomized trials comparing generic and brand-name drugs: a survey. Mayo Clin Proc. 2016;91(8):1021\u201334. https:\/\/doi.org\/10.1016\/j.mayocp.2016.04.032.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1712_CR17","doi-asserted-by":"publisher","first-page":"MR000006","DOI":"10.1002\/14651858.MR000006.pub3","volume":"2009","author":"S Hopewell","year":"2009","unstructured":"Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009;2009(1):MR000006. https:\/\/doi.org\/10.1002\/14651858.MR000006.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1712_CR18","unstructured":"Coates J. Independent review of PHARMAC\u2019s lamotrigine sole supply decision [Internet]. Claro Law; 2020 [accessed 2026 May 23]. https:\/\/www.pharmac.govt.nz\/news-and-resources\/news\/independent-review-of-lamotrigine-sole-supply-decision-by-pharmac."},{"key":"1712_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2025.100630","volume":"19","author":"K Humphreys","year":"2025","unstructured":"Humphreys K, Lin M, Barnes K, Hasan Y, Vignaraja A, Sarna K, et al. Not so great expectations: the role of price and name information in the nocebo effect. Explor Res Clin Soc Pharm. 2025;19:100630. https:\/\/doi.org\/10.1016\/j.rcsop.2025.100630.","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"10","key":"1712_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023667","volume":"8","author":"K MacKrill","year":"2018","unstructured":"MacKrill K, Petrie KJ. What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey. BMJ Open. 2018;8(10):e023667. https:\/\/doi.org\/10.1136\/bmjopen-2018-023667.","journal-title":"BMJ Open"},{"issue":"3","key":"1712_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.healthpol.2016.12.011","volume":"121","author":"T Balasopoulos","year":"2017","unstructured":"Balasopoulos T, Charonis A, Athanasakis K, Kyriopoulos J, Pavi E. Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions. Health Policy (New York). 2017;121(3):265\u201372. https:\/\/doi.org\/10.1016\/j.healthpol.2016.12.011.","journal-title":"Health Policy (New York)."},{"issue":"1","key":"1712_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21642850.2013.803828","volume":"1","author":"S Dohle","year":"2013","unstructured":"Dohle S, Siegrist M. Cognitive and affective determinants of generic drug acceptance and use: cross-sectional and experimental findings. Health Psychol Behav Med. 2013;1(1):5\u201314. https:\/\/doi.org\/10.1080\/21642850.2013.803828.","journal-title":"Health Psychol Behav Med"},{"key":"1712_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/bs.irn.2018.07.016","volume":"139","author":"K Faasse","year":"2018","unstructured":"Faasse K, Martin LR. The power of labeling in nocebo effects. Int Rev Neurobiol. 2018;139:379\u2013406. https:\/\/doi.org\/10.1016\/bs.irn.2018.07.016.","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"1712_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1037\/hea0000282","volume":"35","author":"K Faasse","year":"2016","unstructured":"Faasse K, Martin LR, Grey A, Gamble G, Petrie KJ. Impact of brand or generic labeling on medication effectiveness and side effects. Health Psychol. 2016;35(2):187\u201390. https:\/\/doi.org\/10.1037\/hea0000282.","journal-title":"Health Psychol"},{"issue":"6","key":"1712_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.chembiol.2016.05.013","volume":"23","author":"MS Kinch","year":"2016","unstructured":"Kinch MS, Moore R. Innovator organizations in new drug development: assessing the sustainability of the biopharmaceutical industry. Cell Chem Biol. 2016;23(6):644\u201353. https:\/\/doi.org\/10.1016\/j.chembiol.2016.05.013.","journal-title":"Cell Chem Biol"},{"key":"1712_CR26","unstructured":"NZ Medicines and Medical Devices Safety Authority. Q&A on generic medicines [Internet]. 2020 [accessed 2025 Dec 14]. https:\/\/www.medsafe.govt.nz\/publications\/media\/2019\/Q&AonGenericMedicines%20.asp."},{"key":"1712_CR27","unstructured":"World Health Organization. Procedure for prequalification of pharmaceutical products. WHO Technical Reports Series [Internet]. 2011 [accessed 2026 May 24]. p. 373\u201390. https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/norms-and-standards\/guidelines\/prequalification\/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2."},{"issue":"7","key":"1712_CR28","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.xphs.2016.03.019","volume":"105","author":"CG Abrantes","year":"2016","unstructured":"Abrantes CG, Duarte D, Reis CP. An overview of pharmaceutical excipients: safe or not safe? J Pharm Sci. 2016;105(7):2019\u201326. https:\/\/doi.org\/10.1016\/j.xphs.2016.03.019.","journal-title":"J Pharm Sci"},{"key":"1712_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12050393","author":"J van der Merwe","year":"2020","unstructured":"van der Merwe J, Steenekamp J, Steyn D, Hamman J. The role of functional excipients in solid oral dosage forms to overcome poor drug dissolution and bioavailability. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12050393.","journal-title":"Pharmaceutics"},{"key":"1712_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aaz9906","volume":"369","author":"J Pottel","year":"2020","unstructured":"Pottel J, Armstrong D, Zou L, Fekete A, Huang XP, Torosyan H, et al. The activities of drug inactive ingredients on biological targets. Science. 2020;369:403\u201313. https:\/\/doi.org\/10.1126\/science.aaz9906.","journal-title":"Science"},{"key":"1712_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-1","volume":"14","author":"S Dunne","year":"2013","unstructured":"Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1. https:\/\/doi.org\/10.1186\/2050-6511-14-1.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1712_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2023.100020","volume":"2","author":"PR Dhake","year":"2024","unstructured":"Dhake PR, Kumbhar ST, Gaikwad VL. Biowaiver based on biopharmaceutics classification system: considerations and requirements. Pharm Sci Adv. 2024;2:100020. https:\/\/doi.org\/10.1016\/j.pscia.2023.100020.","journal-title":"Pharm Sci Adv"},{"issue":"2","key":"1712_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cpt.591","volume":"103","author":"RA Hansen","year":"2018","unstructured":"Hansen RA, Qian J, Berg RL, Linneman JG, Seoane-Vazquez E, Dutcher S, et al. Comparison of outcomes following a switch from a brand to an authorized versus independent generic drug. Clin Pharmacol Ther. 2018;103(2):310\u20137. https:\/\/doi.org\/10.1002\/cpt.591.","journal-title":"Clin Pharmacol Ther"},{"key":"1712_CR34","unstructured":"U.S. Food and Drug Administration. FDA List of Authorized Generic Drugs [Internet]. 2026 [accessed 2026 Feb 8]. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/fda-list-authorized-generic-drugs."},{"issue":"4","key":"1712_CR35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s11096-018-0657-1","volume":"40","author":"G Fornasier","year":"2018","unstructured":"Fornasier G, Francescon S, Leone R, Baldo P. An historical overview over pharmacovigilance. Int J Clin Pharm. 2018;40(4):744\u20137. https:\/\/doi.org\/10.1007\/s11096-018-0657-1.","journal-title":"Int J Clin Pharm"},{"key":"1712_CR36","unstructured":"NZ Medicines and Medical Devices Safety Authority. What is Medsafe? [Internet]. 2020 [accessed 2025 Oct 12]. https:\/\/www.medsafe.govt.nz\/other\/about.asp."},{"key":"1712_CR37","unstructured":"NZ Medicines and Medical Devices Safety Authority. Guideline on the regulation of therapeutic products in New Zealand, part 8: pharmacovigilance [Internet]. 2020 [accessed 2026 May 24]. https:\/\/www.medsafe.govt.nz\/regulatory\/guideline\/grtpnz\/part-8-pharmacovigilance.pdf."},{"key":"1712_CR38","unstructured":"Pharmaceutical Management Agency. Background [Internet]. 2020 [accessed 2025 Dec 14]. https:\/\/www.pharmac.govt.nz\/medicine-funding-and-supply\/the-funding-process\/policies-manuals-and-processes\/economic-analysis\/prescription-for-pharmacoeconomic-analysis-methods-for-cost-utility-analysis\/1-background."},{"key":"1712_CR39","unstructured":"Pharmaceutical Management Agency. For suppliers: the annual tender [Internet]. 2022 [accessed 2025 Dec 14]. https:\/\/www.pharmac.govt.nz\/medicine-funding-and-supply\/the-funding-process\/procurement-processes\/the-annual-tender\/the-annual-tender-for-suppliers."},{"key":"1712_CR40","unstructured":"NZ Medicines and Medical Devices Safety Authority. Update on suspected adverse reaction reports to lamotrigine after changing brands [Internet]. 2019 [accessed 2025 Dec 14]. https:\/\/www.medsafe.govt.nz\/safety\/Alerts\/LamotrigineDec2019.asp."},{"key":"1712_CR41","unstructured":"Centre for Adverse Reactions Monitoring (CARM). Adverse events related to lamotrigine brand change to Logem [Internet]. 2019 [accessed 2026 May 24]. https:\/\/www.pharmac.govt.nz\/assets\/Lamotrigine-contingency-plan.pdf."},{"key":"1712_CR42","unstructured":"NZ Medicines and Medical Devices Safety Authority. Eltroxin formulation change [Internet]. 2013 [accessed 2025 Oct 12]. https:\/\/www.medsafe.govt.nz\/hot\/alerts\/EltroxinInfo.asp."},{"key":"1712_CR43","unstructured":"Centre for Adverse Reactions Monitoring (CARM). The Eltroxin formulation change: an analysis of reports received by CARM [Internet]. 2008 [assessed 2025 Oct 12]. https:\/\/www.medsafe.govt.nz\/hot\/alerts\/CARM%20Report%20September%202008.pdf."},{"key":"1712_CR44","unstructured":"Medicines Adverse Reactions Committee. Brand Switches in New Zealand [Internet]. Medsafe; 2018 [accessed 2026 May 23]. https:\/\/www.medsafe.govt.nz\/committees\/marc\/reports\/175-Brand%20Switches%20in%20New%20Zealand.pdf."},{"key":"1712_CR45","unstructured":"NZ Medicines and Medical Devices Safety Authority. Some medicines need to be prescribed by brand [Internet]. 2019 [accessed 2026 Mar 12]. https:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/December2019\/Some-medicines-need-to-be-prescribed-by-brand.htm."},{"issue":"5","key":"1712_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.apsb.2013.07.004","volume":"3","author":"G Boehm","year":"2013","unstructured":"Boehm G, Yao L, Han L, Zheng Q. Development of the generic drug industry in the US after the Hatch-Waxman act of 1984. Acta Pharm Sin B. 2013;3(5):297\u2013311. https:\/\/doi.org\/10.1016\/j.apsb.2013.07.004.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"1712_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/2230-973x.104392","volume":"2","author":"S Handoo","year":"2012","unstructured":"Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. Int J Pharm Investig. 2012;2(3):99\u2013105. https:\/\/doi.org\/10.4103\/2230-973x.104392.","journal-title":"Int J Pharm Investig."},{"key":"1712_CR48","doi-asserted-by":"publisher","first-page":"4680642","DOI":"10.1155\/2016\/4680642","volume":"2016","author":"S Tian","year":"2016","unstructured":"Tian S, Chang HH, Orange D, Gu J, Su\u00e1rez-Fari\u00f1as M. A Bioequivalence test by the direct comparison of concentration-versus-time curves using local polynomial smoothers. Comput Math Methods Med. 2016;2016:4680642. https:\/\/doi.org\/10.1155\/2016\/4680642.","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"1712_CR49","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01159-x","volume":"28","author":"S Lee","year":"2025","unstructured":"Lee S, Baek J, Kang W, Kim E. Regulatory divergence in narrow therapeutic index drugs: a comparative review of the US, EU, Japan, Canada, and South Korea. AAPS J. 2025;28(1):19. https:\/\/doi.org\/10.1208\/s12248-025-01159-x.","journal-title":"AAPS J"},{"issue":"6","key":"1712_CR50","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2125.2011.03925.x","volume":"71","author":"DF Wright","year":"2011","unstructured":"Wright DF, Winter HR, Duffull SB. Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol. 2011;71(6):815\u201323. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03925.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1712_CR51","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1006\/phrs.2000.0719","volume":"42","author":"A Rescigno","year":"2000","unstructured":"Rescigno A. Area under the curve and bioavailability. Pharmacol Res. 2000;42(6):539\u201340. https:\/\/doi.org\/10.1006\/phrs.2000.0719.","journal-title":"Pharmacol Res"},{"key":"1712_CR52","unstructured":"U.S Food and Drug Administration. Orange Book Preface [Internet]. 2025 [accessed 2026 Mar 12]. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/orange-book-preface."},{"issue":"4","key":"1712_CR53","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1208\/s12248-013-9499-x","volume":"15","author":"B Davit","year":"2013","unstructured":"Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 2013;15(4):974\u201390. https:\/\/doi.org\/10.1208\/s12248-013-9499-x.","journal-title":"AAPS J"},{"issue":"3","key":"1712_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/cpt.957","volume":"104","author":"JO Sullivan","year":"2018","unstructured":"Sullivan JO, Blake K, Berntgen M, Salmonson T, Welink J. Overview of the European Medicines Agency\u2019s Development of Product-Specific Bioequivalence Guidelines. Clin Pharmacol Ther. 2018;104(3):539\u201345. https:\/\/doi.org\/10.1002\/cpt.957.","journal-title":"Clin Pharmacol Ther"},{"key":"1712_CR55","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence [Internet]. 2010 [accessed 2026 Mar 12]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"issue":"5","key":"1712_CR56","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1208\/s12248-015-9777-x","volume":"17","author":"R Kuribayashi","year":"2015","unstructured":"Kuribayashi R, Matsuhama M, Mikami K. Regulation of generic drugs in Japan: the current situation and future prospects. AAPS J. 2015;17(5):1312\u20136. https:\/\/doi.org\/10.1208\/s12248-015-9777-x.","journal-title":"AAPS J"},{"key":"1712_CR57","first-page":"805","volume":"53","author":"E Lietzan","year":"2019","unstructured":"Lietzan E. The\" Evergreening\" Metaphor in Intellectual Property Scholarship. Akron Law Rev [Internet]. 2019;53:805.","journal-title":"Akron Law Rev [Internet]."},{"key":"1712_CR58","unstructured":"NZ Medicines and Medical Devices Safety Authority. Guideline on the regulation of therapeutic products in New Zealand, part 6: bioequivalence of medicines [Internet]. 2018 [accessed 2026 May 24]. https:\/\/www.medsafe.govt.nz\/regulatory\/Guideline\/GRTPNZ\/bioequivalence-of-medicines.pdf."},{"issue":"Suppl 5","key":"1712_CR59","first-page":"4","volume":"62","author":"MC Meyer","year":"2001","unstructured":"Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry. 2001;62(Suppl 5):4\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1712_CR60","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/ftd.0000000000000008","volume":"36","author":"S Unterecker","year":"2014","unstructured":"Unterecker S, Proft F, Riederer P, Lauer M, Deckert J, Pfuhlmann B. The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis. Ther Drug Monit. 2014;36(2):269\u201372. https:\/\/doi.org\/10.1097\/ftd.0000000000000008.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"1712_CR61","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00228-015-1878-z","volume":"71","author":"Y Yu","year":"2015","unstructured":"Yu Y, Teerenstra S, Neef C, Burger D, Maliepaard M. Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines. Eur J Clin Pharmacol. 2015;71(8):979\u201390. https:\/\/doi.org\/10.1007\/s00228-015-1878-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1712_CR62","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ejhpharm-2012-000258","volume":"20","author":"A Johnston","year":"2013","unstructured":"Johnston A. Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm. 2013;20(5):302\u20137. https:\/\/doi.org\/10.1136\/ejhpharm-2012-000258.","journal-title":"Eur J Hosp Pharm"},{"issue":"1\u201302","key":"1712_CR63","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0037-1600991","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):e1. https:\/\/doi.org\/10.1055\/s-0037-1600991.","journal-title":"Pharmacopsychiatry"},{"issue":"9","key":"1712_CR64","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s40262-020-00909-8","volume":"59","author":"PJ Glerum","year":"2020","unstructured":"Glerum PJ, Neef C, Burger DM, Yu Y, Maliepaard M. Pharmacokinetics and generic drug switching: a regulator\u2019s view. Clin Pharmacokinet. 2020;59(9):1065\u20139. https:\/\/doi.org\/10.1007\/s40262-020-00909-8.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1712_CR65","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1208\/s12248-012-9406-x","volume":"14","author":"BM Davit","year":"2012","unstructured":"Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, Lee CH, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J. 2012;14(4):915\u201324. https:\/\/doi.org\/10.1208\/s12248-012-9406-x.","journal-title":"AAPS J"},{"key":"1712_CR66","unstructured":"European Medicines Agency. Questions and answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP) [Internet]. 2015 [accessed 2025 Oct 12]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf."},{"issue":"3","key":"1712_CR67","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/clpt.2010.90","volume":"88","author":"JJ Gagne","year":"2010","unstructured":"Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010;88(3):347\u201353. https:\/\/doi.org\/10.1038\/clpt.2010.90.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1712_CR68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1592\/phco.29.7.769","volume":"29","author":"KL Rascati","year":"2009","unstructured":"Rascati KL, Richards KM, Johnsrud MT, Mann TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy. 2009;29(7):769\u201374. https:\/\/doi.org\/10.1592\/phco.29.7.769.","journal-title":"Pharmacotherapy"},{"key":"1712_CR69","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.seizure.2021.05.011","volume":"91","author":"G Kr\u00e4mer","year":"2021","unstructured":"Kr\u00e4mer G, Steinhoff BJ. The times they are a-changin - don\u2019t panic with a generic! Seizure. 2021;91:513\u20134. https:\/\/doi.org\/10.1016\/j.seizure.2021.05.011.","journal-title":"Seizure"},{"issue":"10","key":"1712_CR70","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1345\/aph.1M141","volume":"43","author":"BM Davit","year":"2009","unstructured":"Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583\u201397. https:\/\/doi.org\/10.1345\/aph.1M141.","journal-title":"Ann Pharmacother"},{"key":"1712_CR71","unstructured":"Clinical Pharmacogenetics Implementation Consortium. Genes-Drugs [Internet]. 2025 [accessed 2025 Nov 08]. https:\/\/cpicpgx.org\/genes-drugs\/."},{"key":"1712_CR72","unstructured":"ClinPGx. CPIC Guidelines [Internet]. 2026 [accessed 2026 May 23]. https:\/\/www.clinpgx.org\/cpic\/guidelines."},{"key":"1712_CR73","doi-asserted-by":"publisher","DOI":"10.31531\/2581-4745.1000111","author":"JT Oates","year":"2018","unstructured":"Oates JT, Lopez D. Pharmacogenetics: an important part of drug development with a focus on its application. Int J Biomed Investig. 2018. https:\/\/doi.org\/10.31531\/2581-4745.1000111.","journal-title":"Int J Biomed Investig."},{"key":"1712_CR74","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-981-15-3895-7_14","volume-title":"Pharmacogenomics in precision medicine: from a perspective of ethnic differences","author":"X Xiang","year":"2020","unstructured":"Xiang X, Yuan Y. Application of pharmacogenomics in drug discovery and development. In: Cai W, Liu Z, Miao L, Xiang X, editors. Pharmacogenomics in precision medicine: from a perspective of ethnic differences. Singapore: Springer Singapore; 2020. p. 257\u201376. https:\/\/doi.org\/10.1007\/978-981-15-3895-7_14."},{"issue":"1","key":"1712_CR75","doi-asserted-by":"publisher","DOI":"10.4155\/ipk-2020-0002","volume":"5","author":"PJ Huang","year":"2020","unstructured":"Huang PJ, Hsieh Y, Huang YW, Ding L, Liu C, Shen B, et al. Pharmacogenetic perspectives in improving pharmacokinetic profiles for efficient bioequivalence trials with highly variable drugs: a review. Int J Pharmacokinet. 2020;5(1):IPK02. https:\/\/doi.org\/10.4155\/ipk-2020-0002.","journal-title":"Int J Pharmacokinet"},{"issue":"5","key":"1712_CR76","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","volume":"32","author":"LE Kristensen","year":"2018","unstructured":"Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32(5):397\u2013404. https:\/\/doi.org\/10.1007\/s40259-018-0306-1.","journal-title":"BioDrugs"},{"issue":"1","key":"1712_CR77","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-pharmtox-022723-112425","volume":"64","author":"L Colloca","year":"2024","unstructured":"Colloca L. The nocebo effect. Annu Rev Pharmacol Toxicol. 2024;64(1):171\u201390. https:\/\/doi.org\/10.1146\/annurev-pharmtox-022723-112425.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"1712_CR78","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.amjmed.2022.06.007","volume":"135","author":"ME Tavel","year":"2022","unstructured":"Tavel ME. Nocebo vs placebo effects: their clinical relevance. Am J Med. 2022;135(11):1296\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2022.06.007.","journal-title":"Am J Med"},{"issue":"5","key":"1712_CR79","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/tpj.2012.29","volume":"13","author":"N Gonzalez-Vacarezza","year":"2013","unstructured":"Gonzalez-Vacarezza N, Abad-Santos F, Carcas-Sansuan A, Dorado P, Penas-Lledo E, Estevez-Carrizo F, et al. Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. Pharmacogenom J. 2013;13(5):452\u20135. https:\/\/doi.org\/10.1038\/tpj.2012.29.","journal-title":"Pharmacogenom J."},{"issue":"2","key":"1712_CR80","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5414\/CP203297","volume":"57","author":"M Oh","year":"2019","unstructured":"Oh M, Yeo CW, Kim HS, Shon J, Shin JG. Genotype-based enrichment study design for minimizing the sample size in bioequivalence studies using tolterodine and CYP2D6 genotype. Int J Clin Pharmacol Ther. 2019;57(2):110\u20136. https:\/\/doi.org\/10.5414\/CP203297.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"1712_CR81","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13318-017-0459-1","volume":"43","author":"Y Chen","year":"2018","unstructured":"Chen Y, Deng Y, Yan M, Hou Z, Li Y, Zhang B, et al. Genotyping as a key element of sample size optimization in bioequivalence of risperidone tablets. Eur J Drug Metab Pharmacokinet. 2018;43(4):431\u20139. https:\/\/doi.org\/10.1007\/s13318-017-0459-1.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"1712_CR82","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/jcph.70058","volume":"65","author":"J Bae","year":"2025","unstructured":"Bae J, Shon J, Kim MJ, Li K. Pharmacogenetic approaches to optimize bioequivalence studies in generic drug development. J Clin Pharmacol. 2025;65(11):1598\u2013608. https:\/\/doi.org\/10.1002\/jcph.70058.","journal-title":"J Clin Pharmacol"},{"key":"1712_CR83","unstructured":"New Zealand Institute of Economic Research. Health priorities? A comparison of New Zealand\u2019s public health and disability expenditure against selected OECD countries [Internet]. 2025 [accessed 2026 Jun 5]. https:\/\/www.nzier.org.nz\/hubfs\/Public%20Publications\/Client%20reports\/Health%20Priorities_NZIER%20final%20report%20October%202025.pdf."},{"key":"1712_CR84","unstructured":"U.S Food and Drug Administration. Product-specific guidances for generic drug development [Internet]. 2026 [accessed 2026 May 23]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/psg\/index.cfm?event=Home.Search#letterSearchBar."},{"key":"1712_CR85","unstructured":"Medicines and Healthcare products Regulatory Agency. Antiepileptic drugs: updated advice on switching between different manufacturers\u2019 products [Internet]. 2017 [accessed 2026 May 23]. https:\/\/www.gov.uk\/drug-safety-update\/antiepileptic-drugs-updated-advice-on-switching-between-different-manufacturers-products."},{"issue":"6","key":"1712_CR86","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.bja.2022.03.007","volume":"128","author":"TD Egan","year":"2022","unstructured":"Egan TD. The drug titration paradox: something obvious finally understood. Br J Anaesth. 2022;128(6):900\u20132. https:\/\/doi.org\/10.1016\/j.bja.2022.03.007.","journal-title":"Br J Anaesth"},{"key":"1712_CR87","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620958910","author":"AR Caffrey","year":"2020","unstructured":"Caffrey AR, Borrelli EP. The art and science of drug titration. Ther Adv Drug Saf. 2020. https:\/\/doi.org\/10.1177\/2042098620958910.","journal-title":"Ther Adv Drug Saf."},{"issue":"Suppl 1","key":"1712_CR88","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s40258-014-0146-1","volume":"13","author":"R Alfonso-Cristancho","year":"2015","unstructured":"Alfonso-Cristancho R, Andia T, Barbosa T, Watanabe JH. Definition and classification of generic drugs across the world. Appl Health Econ Health Policy. 2015;13(Suppl 1):S5-11. https:\/\/doi.org\/10.1007\/s40258-014-0146-1.","journal-title":"Appl Health Econ Health Policy"},{"key":"1712_CR89","unstructured":"U.S Food and Drug Administration. 2019 Office of Generic Drugs annual report [Internet]. 2020 [accessed 2025 Aug 15]. https:\/\/www.fda.gov\/drugs\/generic-drugs\/2019-office-generic-drugs-annual-report."},{"key":"1712_CR90","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Bioequivalence for immediate-release solid oral dosage forms M13A Draft Version [Internet]. 2024 [accessed 2025 Aug 15]. https:\/\/www.fda.gov\/media\/165049\/download."},{"issue":"3","key":"1712_CR91","doi-asserted-by":"publisher","first-page":"e1002763","DOI":"10.1371\/journal.pmed.1002763","volume":"16","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, et al. Comparative effectiveness of generic and brand-name medication use: a database study of US health insurance claims. PLoS Med. 2019;16(3):e1002763. https:\/\/doi.org\/10.1371\/journal.pmed.1002763.","journal-title":"PLoS Med"},{"key":"1712_CR92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eplepsyres.2017.06.007","volume":"135","author":"MM Rahman","year":"2017","unstructured":"Rahman MM, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, et al. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Epilepsy Res. 2017;135:71\u20138. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.06.007.","journal-title":"Epilepsy Res"},{"key":"1712_CR93","unstructured":"Grand View Research. Generic Pharmaceuticals Market (2026\u20132033) [Internet]. 2026 [accessed 2026 May 23]. https:\/\/www.grandviewresearch.com\/industry-analysis\/generic-pharmaceuticals-market-report."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01712-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:02:37Z","timestamp":1791003757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01712-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":93,"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01712-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.177140889.99997579\/v1","asserted-by":"object"}]},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is an opinion piece which uses previously published data with no personal identifiers or involvement of human subjects.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No human subjects were involved.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No human subjects were involved.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current writing.","order":5,"name":"Ethics","label":"Availability of data and material (data transparency)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"*PK: writing\u2014original draft, conceptualisation; *MK, SM, PC: writing\u2014review and editing, conceptualisation; *MT: writing\u2014review and editing, conceptualisation, CARM data resources; *RB: writing\u2014review and editing; All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}